Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS)
Unknown statusNot applicableNCT02556411
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Adenomyosis is characterized by the appearance of endometrial cells in the muscular layer of the uterus. It affects about 15-20% of the female population. The symptoms of adenomyosis are heavy menstrual bleedings and painful menstruation (dysmenorrhea) and in addition chronic pelvic pain. Regarding treatment levonogestrel-releasing intrauterine system, Gonadotropin releasing hormone (GnRH)-analogues, Danazol, uterine embolization and endometrial ablation have been tried. The aim of this study is to compare the efficacy and usefulness of association of oral contraceptive pill and LNG-IUS or LNG-IUS alone
Study details
- Official title
- Comparison of E/P Therapy in Continuous Regimen Versus Combination of LNG-IUS Plus E/P
- Conditions
- Adenomyosis
- Chronic Pelvic Pain
- Interventions
- Drug: LNG-IUS 13,5 mg Levonorgestrel
- Drug: Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
- Sponsor
- University of Cagliari
- Start date
- 2021-06-01
- Primary completion
- 2021-12-01
- Sex
- Female
- Age range
- from 18 Years to 40 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Women affected by adenomyosis with pelvic pain \> 4; * Negative Pap Smear test Exclusion Criteria: * Pregnancy or research of pregnancy * Refusal or inability to sign informed consent * Severe underlying comorbidities (hepatic, oncological) * Pelvic inflammatory disease * Other cervical or uterine pathologies * Deep venous thromboembolism * Hormonal therapy contraindications * Smoke
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02556411